M9466

M9466 (HRS-1167) is a highly potent and selective small molecule inhibitor of poly (ADP-ribose) polymerase 1 (PARP1) with DNA trapping activity. Developed by Jiangsu Hengrui Pharmaceuticals and licensed by EMD Serono (Merck KGaA), it is designed as a next-generation PARP inhibitor to overcome limitations of first-generation inhibitors, which often target both PARP1 and PARP2. By specifically targeting the PARP1 isoform, M9466 aims to improve the therapeutic index by potentially reducing hematological toxicities associated with PARP2 inhibition. It is currently being evaluated in Phase I clinical trials for the treatment of advanced solid tumors, including colorectal cancer, prostate cancer, and small-cell lung cancer, both as a monotherapy and in combination with chemotherapy regimens such as topoisomerase 1 inhibitors (e.g., irinotecan) and targeted agents like bevacizumab.

Other names

HRS1167HRS-1167HRS 1167